Clinical Trial Update: Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating ruxolitinib in combination with preoperative chemotherapy for triple-negative inflammatory breast cancer; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Inflammatory Breast Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-21